Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP's Annual MLK Jr.

The global composite decking market size is estimated to grow by USD 3.99 billion from 2025 to 2029, according to Technavio. The market is estimated to grow at a CAGR of 16.6% during the forecast ...

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome ...

Arrowhead’s plozasiran, meanwhile, showed its worth in the phase 2b SHASTA-2 study in severe HTG patients at risk of acute pancreatitis, with an average 74% reduction in triglyceride levels at ...

There is potential competition on the way from Arrowhead Pharma, whose plozasiran was submitted for approval with the FDA as a treatment for FCS in November.